COFCO Biotechnology Co., Ltd.
000930.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.95 | 0.13 | -2.52 | 0.20 |
| FCF Yield | -3.17% | 10.71% | 0.91% | 18.40% |
| EV / EBITDA | 21.13 | 310.73 | 9.05 | 10.65 |
| Quality | ||||
| ROIC | 0.16% | -4.39% | 6.66% | 7.40% |
| Gross Margin | 5.71% | 2.85% | 10.45% | 10.34% |
| Cash Conversion Ratio | 3.41 | -3.25 | 0.67 | 4.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.23% | -4.72% | 0.01% | 6.56% |
| Free Cash Flow Growth | -124.75% | 827.69% | -96.18% | 195.73% |
| Safety | ||||
| Net Debt / EBITDA | 4.03 | 48.40 | 1.12 | 1.08 |
| Interest Coverage | 0.66 | -5.08 | 14.87 | 8.53 |
| Efficiency | ||||
| Inventory Turnover | 6.83 | 7.81 | 4.74 | 5.21 |
| Cash Conversion Cycle | 64.22 | 52.71 | 85.44 | 76.62 |